All In Biotech

Drug Trial Radar · NCT06888362

Trial to Investigate GZ21T in Healthy Volunteers

A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

41

Actual

Start

Aug 19, 2024

Primary completion

Mar 31, 2025

Study completion Mar 31, 2025

Sponsor

Sponsor type
Industry
Collaborators
CTC Clinical Trial Consultants AB
First posted
Mar 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, randomised, placebo-controlled trial designed to evaluate safety, tolerability, and pharmacokinetics (PK) after topical administration of single ascending doses of GZ21T in healthy volunteers.

Conditions

  • Actinic Keratosis

Interventions

  • GZ21TDrug

    GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AETime frame: Day 1 to Day 7
  2. Number of Reported Skin ReactionsTime frame: Day 1 to Day 7.
  3. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Day 1 to Day 7.
  4. Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)Time frame: Day 1 to Day 7.
  5. Number of Participants With Clinically Significant Abnormal Laboratory Test Results (Haematology, Clinical Chemistry, Coagulation)Time frame: Day 1 to Day 7.
  6. Number of Participants With Clinically Significant Changes in Physical Examination Findings.Time frame: Day 1 to Day 7.
  7. Amount of Cream Absorbed After Single Dose Applications.Time frame: 0-2 hours after IMP administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC (Clinical Trial Consultants) AB

    Uppsala, Sweden, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.